These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 19151)

  • 61. Preparing cancer patients to administer medication.
    Thomas NP; Cloak M; Crosson K; Kwan J
    Patient Couns Health Educ; 1982 4th Quart; 3(4):137-43. PubMed ID: 10295167
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dermatologic uses of methotrexate in children: indications and guidelines.
    Paller AS
    Pediatr Dermatol; 1985 Mar; 2(3):238-43. PubMed ID: 3887343
    [TBL] [Abstract][Full Text] [Related]  

  • 63. High dose methotrexate treatment and its problems. A workshop held in Sydney, Australia in December 1977.
    Clin Exp Pharmacol Physiol; 1979; (5):1-61. PubMed ID: 38025
    [No Abstract]   [Full Text] [Related]  

  • 64. Trimethoprim and folinic acid.
    Kinzie BJ; Taylor JW
    Ann Intern Med; 1984 Oct; 101(4):565. PubMed ID: 6332566
    [No Abstract]   [Full Text] [Related]  

  • 65. Pharmacologic studies of methotrexate in cancer patients with uropathy.
    Ojima Y; Anderson LL; Collins GJ; Oberfield RA; Sullivan RD
    Arch Surg; 1970 Feb; 100(2):173-7. PubMed ID: 5411410
    [No Abstract]   [Full Text] [Related]  

  • 66. Methotrexate.
    O'Marcaigh AS; Betcher DL
    J Pediatr Oncol Nurs; 1993 Oct; 10(4):158-60. PubMed ID: 8251124
    [No Abstract]   [Full Text] [Related]  

  • 67. HEMATOLOGIC ASPECTS OF RENAL DISEASE.
    LEIKIN SL
    Pediatr Clin North Am; 1964 Aug; 11():667-84. PubMed ID: 14328544
    [No Abstract]   [Full Text] [Related]  

  • 68. [ON THE PROGNOSIS AND THERAPY OF CHRONIC DISEASES UNDER SPECIAL CONSIDERATION OF BLOOD AND KIDNEY DISEASES].
    OEHME J
    Med Welt; 1964 May; 21():1173-82. PubMed ID: 14228724
    [No Abstract]   [Full Text] [Related]  

  • 69. Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.
    Ghannoum M; Roberts DM; Goldfarb DS; Heldrup J; Anseeuw K; Galvao TF; Nolin TD; Hoffman RS; Lavergne V; Meyers P; Gosselin S; Botnaru T; Mardini K; Wood DM;
    Clin J Am Soc Nephrol; 2022 Apr; 17(4):602-622. PubMed ID: 35236714
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections.
    Wright KD; Panetta JC; Onar-Thomas A; Reddick WE; Patay Z; Qaddoumi I; Broniscer A; Robinson G; Boop FA; Klimo P; Ward D; Gajjar A; Stewart CF
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):27-35. PubMed ID: 25342291
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments.
    Pauley JL; Panetta JC; Crews KR; Pei D; Cheng C; McCormick J; Howard SC; Sandlund JT; Jeha S; Ribeiro R; Rubnitz J; Pui CH; Evans WE; Relling MV
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):369-78. PubMed ID: 23760811
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Glutamine: A novel approach to chemotherapy-induced toxicity.
    Gaurav K; Goel RK; Shukla M; Pandey M
    Indian J Med Paediatr Oncol; 2012 Jan; 33(1):13-20. PubMed ID: 22754203
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prevention of chronic radiation enteropathy by dietary glutamine.
    Jensen JC; Schaefer R; Nwokedi E; Bevans DW; Baker ML; Pappas AA; Westbrook KC; Klimberg VS
    Ann Surg Oncol; 1994 Mar; 1(2):157-63. PubMed ID: 7834441
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Glutamine enhances selectivity of chemotherapy through changes in glutathione metabolism.
    Rouse K; Nwokedi E; Woodliff JE; Epstein J; Klimberg VS
    Ann Surg; 1995 Apr; 221(4):420-6. PubMed ID: 7726679
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacokinetics of oral and intramuscular methotrexate in children with acute lymphoblastic leukaemia.
    Pearson AD; Mills S; Amineddine HA; Long DR; Craft AW; Chessells JM
    Cancer Chemother Pharmacol; 1987; 20(3):243-7. PubMed ID: 3315283
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Survival after unexpected high serum methotrexate concentrations in a patient with osteogenic sarcoma.
    Grimes DJ; Bowles MR; Buttsworth JA; Thomson DB; Ravenscroft PJ; Nixon PF; Whiting RF; Pond SM
    Drug Saf; 1990; 5(6):447-54. PubMed ID: 2285498
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacokinetic and clinical studies of 24-h infusions of high-dose methotrexate.
    Cohen HJ; Jaffe N
    Cancer Chemother Pharmacol; 1978; 1(1):61-4. PubMed ID: 373909
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients.
    Evans WE; Pratt CB; Taylor RH; Barker LF; Crom WR
    Cancer Chemother Pharmacol; 1979; 3(3):161-6. PubMed ID: 316744
    [No Abstract]   [Full Text] [Related]  

  • 79. Recovery from toxicity associated with high-dose methotrexate: prognostic factors.
    Chan H; Evans WE; Pratt CB
    Cancer Treat Rep; 1977 Aug; 61(5):797-804. PubMed ID: 19151
    [No Abstract]   [Full Text] [Related]  

  • 80. High-dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity.
    Nirenberg A; Mosende C; Mehta BM; Gisolfi AL; Rosen G
    Cancer Treat Rep; 1977 Aug; 61(5):779-83. PubMed ID: 302143
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.